- All
- Drug Resistance - HAI
- Gastrointestional Infections
- HPV
- Meningitis
- Respiratory Infections
- Sexual Transmitted Infections
- Streptococcal Infection
- Tuberculosis
Association between HPV infection and penile cancer and penile intraepithelial neoplasia: A retrospective observational study
1st Author: Guimaraes MJ, Macieira R, Azevedo F, Lisboa C. (2024)
Key point:
Penile cancer is rising in most European countries. Several risk factors have been identified, namely human papillomavirus (HPV) infection. However, the exact role of HPV in penile cancer carcinogenesis is still unknown. Clarifying the contribution of HPV in penile cancer is crucial as it may improve prevention and treatment strategies.
Molecular Genotyping of Human Papillomavirus (HPV) in Hypopharyngeal Cancer
1st Author: Faye, B., Diabira, S., Bassoum, et al. (2023)
Key point:
Molecular HPV detection and genotyping were performed by multiplex RT-PCR with the Seegene Anyplex™ II HPV28 kit Detection on a Biorad CFX96 automaton according to the manufacturer’s protocol for the simultaneous genotyping of 28 types of HPV including 19 at High Risk (HR) and 9 low risk (LR).
Prevalence and Risk Factors for High-Risk Human Papillomavirus Infection and Cervical Disorders: Baseline Findings From an Human Papillomavirus Cohort Study
1st Author: Saldaña-Rodríguez P, Bahena-Román M, Delgado-Romero K, et al. (2023)
Key point:
A persistent infection by high-risk human papillomavirus (HR-HPV) is a prerequisite for the development of cervical neoplasms; however, most studies have focused on risk factors associated with HPV-16 and HPV-18 only.
Toward 70% cervical cancer screening coverage: Technical challenges and opportunities to increase access to human papillomavirus (HPV) testing
1st Author: Kundrod KA, Jeronimo J, Vetter B, et al. (2023)
Key point:
The World Health Organization (WHO) has called for the elimination of cervical cancer as a public health problem. Cervical cancer screening through human papillomavirus (HPV) testing is a core component of the strategy for elimination, with a set target of screening 70% of women twice in their lifetimes. In this review, we discuss technical barriers and opportunities to increase HPV screening globally.
Diagnostic performances of four commercially available assays for the identification of SARS-CoV-2, influenza type A/B virus and RSV.
1st Author: Houwen C, van Lisdonk N, Bolier J, et al. (2023)
Key point:
Three Seegene Allplex™ Assays and a Hologic Aptima™ Assay were evaluated.
Excellent performances were shown for SARS-CoV-2, Influenza type A/B virus and RSV.
The extraction-free and LAMP assays allow increased testing capacity/productivity.
TTime is a new result parameter, which may be used as a surrogate for Ct-value.
Retrospective and Comparative Study of Three Molecular Assays for the Macrolide Resistance Detection in Mycoplasma genitalium Positive Urogenital Specimens
1st Author: Maldonado-Barrueco A, Sanz-González C, Falces-Romero I, et al. (2023)
Key point:
The capacity of Mycoplasma genitalium to develop resistance to macrolides makes detection of macrolide resistance genes by rapid real-time PCR assays increasingly necessary in clinical diagnostic laboratories so as to initiate appropriate treatment as rapidly as possible. The aim of this retrospective and comparative study was to conduct the clinical evaluation of three commercially available kits for macrolide resistance detection.
Description of pathogenic bacteria in patients with respiratory symptoms associated with severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in Colombia
1st Author: Zuluaga N, Martínez D, Hernández C, et al. (2023)
Key point:
In this study, pathogenic respiratory bacteria were detected using commercial kit Allplex™ Respiratory Panel 4 from nasopharyngeal samples from individuals suffering respiratory symptoms with and without severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Patients without respiratory symptoms were included as controls.
HPV Molecular Genotyping as a Differential Diagnosis Tool in Cervical Cancer Metastasis
1st Author: Montero-Macías R, Coronado PJ, Robillard N, et al. (2023)
Key point:
Differentiating metastatic cervical cancer from another primary tumor can be difficult in patients with a history of cervical cancer and a distant lesion. The use of routine HPV molecular detection and genotyping tests could help in these cases.
Clinical Performance of Three Commercial Molecular Diagnostic Assays for the Detection of Fluoroquinolone Resistance-Associated Mutations in Mycoplasma genitalium
1st Author: Gardette M, Hénin N, Le Roy C, et al. (2022)
Key point:
In the absence of Ser83Ile (G248T) and mutations at position at 83 and 87 in parC, the probability of moxifloxacin cure of macrolide-resistant Mycoplasma genitalium was 96.4% and 97.8%, respectively. This suggests that selection of antibiotics via testing the existence of parC mutation using Allplex™ MG & MoxiR Assay is essential in increasing the treatment efficiency of Mycoplasma genitalium.
Low prevalence of macrolide resistance in Mycoplasma genitalium infections in a cohort of pregnant women living with human immunodeficiency virus
1st Author: Ngobese B, Swe Swe-Han K, Tinarwo P, et al. (2022)
Key point:
Macrolide resistance in Mycoplasma genitalium (M. genitalium) is increasing as a result of the widespread use of azithromycin in the treatment of sexually transmitted infections (STIs). To date, there are few published studies on macrolide resistance patterns in South African pregnant women. This study now contributes to the growing body of knowledge.
Performance of two commercial multiplex polymerase chain reaction assays for the etiological diagnosis of sexually transmitted infections among men who have sex with men
1st Author: Lee TF, Lin KY, Chang SY, et al. (2022)
Key point:
This paper supports the performance of Allplex™ STI Essential Assay as syndromic testing. Allplex™ STI Essential Assay can detect pathogens as MG, MH, and UU, and there were single infections of these pathogens among the study population.
The yield of CSF molecular testing in febrile neonates
Rapid detection of antimicrobial resistance markers with Allplex™ Entero-DR assay directly from positive blood culture bottles
1st Author: Hannus P, Räisänen K, Martelin JJ. (2021)
Key point:
Allplex™ Entero-DR assay approach shortens the time to detection compared to conventional techniques for the detection of antimicrobial resistance, therefore enabling early implementation of infection control measures in hospitalized patients.
Cepheid Xpert® Flu/RSV and Seegene Allplex™ RP1 show high diagnostic agreement for the detection of influenza A/B and respiratory syncytial viruses in clinical practice
1st Author: Wabe N, Lindeman R, Post JJ, et al. (2020)
Key point:
Molecular assays based on reverse transcription-polymerase chain reaction (RT-PCR) provide reliable results for the detection of respiratory pathogens, although diagnostic agreement varies. This study determined the agreement between the RT-PCR assays (Xpert® Flu/RSV vs Allplex™ RP1) in detecting influenza A, influenza B, and respiratory syncytial viruses (RSVs) in clinical practice.
Treatment for Epstein-Barr Virus-associated uveitis confirmed by polymerase chain reaction: Efficacy of Anti-Viral Agents and a literature review
1st Author: Sukhum Silpa-Archa et al. (2022)
Key point:
Our study and review of the literature concurred that there was an absence of EBV DNA in the eyes of healthy controls, while pathogenicity of EBV in uveitis patients was confirmed.
In uveitis patients, EBV can be solely present or can co-exist with other pathogens.
The efficacy levels of systemic acyclovir for the treatment of EBV-associated uveitis patients were confirmatory, while systemic acyclovir and ganciclovir had comparable EBV viral suppression effects.
A stepwise algorithm has been proposed to help ophthalmologists in the management of EBV-associated intraocular inflammation.
Evaluation of Allplex™ Entero-DR assay for detection of antimicrobial resistance determinants from bacterial cultures
1st Author: Mojica MF, De La Cadena E, Correa A, et al. (2020)
Key point:
Comparison with the results previously obtained by means of the in-house qPCR assay and WGS, Allplex™ Entero-DR Assay revealed that all tested isolates carrying resistant genes were correctly identified. The calculated sensitivity and specificity of the assay were 100% and 92–100%, respectively.
Evaluation of Anyplex™ II MTB/MDR Kit’s Performance to Rapidly Detect Isoniazid and Rifampicin Resistant Mycobacterium tuberculosis from Various Clinical Specimens
1st Author: Chumpa N, Kawkitinarong K, Rotcheewaphan S, et al. (2020)
Key point:
This study showed that the PPV of Anyplex™ II MTB/MDR Detection in predicting Hr-TB infection was 93.5%. Anyplex™ II MTB/MDR Detection has a high accuracy rate in detecting drug-resistant tuberculosis. Since the PPV was greater than 90%, this indicated that the Anyplex™ II MTB/MDR Detection will be useful in countries with high TB burden because it will be able to detect Hr-TB.
Clinical performance of Anyplex™ II HPV28 by human papillomavirus type and viral load in a referral population
1st Author: Baasland I, Romundstad PR, Eide ML, et al. (2019)
Key point:
Human papillomavirus (HPV) infection is the main cause of cervical intraepithelial neoplasia (CIN) and invasive cervical cancer (ICC). More than 200 HPV types have been identified, including approximately 40 that preferentially infect the genital tract. Genital HPV are subdivided into low-risk (LR-HPV) types, which are principally found in non-malignant lesions, and high-risk (HR-HPV) types, which are associated with the development of CIN and ICC. Currently, 12 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are classified as carcinogenic, and HPV 68 is considered as probably carcinogenic by the International Agency for Research on Cancer (IARC). Molecular detection of these HR-HPV is the key of cervical cancer screening. Recently, a new multiplex real-time PCR kit, Allplex™ HPV28 (Seegene, Korea), has been commercialized. This study aims to evaluate its clinical performance for HPV screening and genotyping in comparison with Anyplex ™ II HPV28 (Seegene, Korea).